Our Pipeline

Pipeline icon

Leading the Way in Cell Therapy

Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.

PROGRAM

PHASE

  • PHASE 1
  • PHASE 2
  • PHASE 3
  • NDA / BLA / MAA

Axicabtagene ciloleucel

  • PHASE 3

Trial:

ZUMA-7

 

2L DLBCL

Axicabtagene ciloleucel

  • PHASE 2

Trial:

ZUMA-5

 

Indolent NHL

Axicabtagene ciloleucel

  • PHASE 2

Trial:

ZUMA-14

 

DLBCL (+rituximab or lenalidomide)

Axicabtagene ciloleucel

  • PHASE 2

Trial:

ZUMA-12

 

1L HR DLBCL

Axicabtagene ciloleucel

  • PHASE 1

Trial:

ZUMA-11

 

DLBCL (+utomilumab)

KTE-X19

  • BLA / MAA

Trial:

ZUMA-2

 

MCL

KTE-X19

  • PHASE 2

Trial:

ZUMA-3

 

Adult ALL

KTE-X19

  • PHASE 2

Trial:

ZUMA-4

 

Pediatric ALL

KTE-X19

  • PHASE 2

Trial:

ZUMA-8

 

CLL

KITE-718 (MAGE A3/A6)

  • PHASE 1

Trial:

N/A

 

Solid Tumor

KITE-439 (HPV16 E7)

  • PHASE 1

Trial:

N/A

 

Solid Tumor

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.